Marizyme CEO Delivers Business Update
JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel:
Related news for (MRZM)
- Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
- InvestmentPitch Media Video Features Marizyme’s CEO David Barthel Discussing Receipt of FDA Clearance for its Flagship DuraGraft Medical Device
- The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News